SSRI Selection with Rexulti for Anxiety and Cannabis-Induced Psychosis History
For a patient with anxiety and a history of cannabis-induced psychosis who is on brexpiprazole (Rexulti), sertraline or escitalopram are the preferred SSRIs, as they avoid the significant drug interaction concerns posed by paroxetine and fluoxetine.
Key Drug Interaction Considerations
The FDA label for Rexulti explicitly addresses SSRI combinations 1. Critically, paroxetine and fluoxetine are strong CYP2D6 inhibitors that significantly increase brexpiprazole exposure. However, there's an important caveat: the FDA notes that in clinical trials for major depressive disorder (MDD), Rexulti dosing was NOT adjusted for strong CYP2D6 inhibitors like paroxetine and fluoxetine, meaning these interactions are already factored into standard dosing recommendations for MDD 1.
Practical Algorithm for SSRI Selection:
First-line choices (no dose adjustment needed):
- Sertraline - No CYP2D6 inhibition, supported by preclinical evidence with brexpiprazole 2
- Escitalopram - Minimal CYP2D6 inhibition, specifically studied with brexpiprazole in PTSD models showing synergistic anxiolytic effects 2
Second-line (requires careful consideration):
- Paroxetine or Fluoxetine - Can be used WITHOUT Rexulti dose adjustment specifically in MDD/anxiety contexts per FDA labeling 1, but this creates higher brexpiprazole exposure
Avoid:
- Fluvoxamine (strong CYP3A4 inhibitor) - Would require Rexulti dose reduction 1
Evidence Supporting the Combination
Preclinical studies demonstrate that brexpiprazole combined with SSRIs produces superior anxiolytic effects compared to either agent alone 3, 2. Specifically:
- The combination of brexpiprazole (0.1 mg/kg) and paroxetine (0.75 mg/kg) significantly reduced anxiety-like behaviors in the marble-burying test, while neither agent was effective alone 3
- In PTSD models (relevant given the psychosis history), brexpiprazole + escitalopram showed significant benefits over monotherapy on anxiety-like behaviors and hyperalertness 2
- A 2026 meta-analysis confirmed brexpiprazole augmentation of SSRIs improved PTSD symptoms (CAPS-5 scores) with acceptable tolerability 4
Clinical Rationale for This Patient
Why this matters for cannabis-induced psychosis history:
The APA schizophrenia guidelines emphasize continuing antipsychotic treatment when symptoms have improved 5. While cannabis-induced psychosis is distinct from schizophrenia, maintaining antipsychotic coverage (brexpiprazole) while treating anxiety is prudent. The combination approach addresses both:
- Anxiety management - SSRIs are first-line per anxiety disorder guidelines 6
- Psychosis prophylaxis - Brexpiprazole provides ongoing dopamine modulation
Monitoring and Safety
Watch for:
- Weight gain and somnolence - More common with brexpiprazole + SSRI combinations 4
- Metabolic parameters - Though the meta-analysis showed no significant triglyceride changes 4
- Extrapyramidal symptoms - Standard antipsychotic monitoring applies 5
Advantages of sertraline or escitalopram:
- Clean pharmacokinetic profile with brexpiprazole
- Established efficacy for anxiety disorders 6
- Preclinical evidence specifically supporting the combination 2
- No Rexulti dose adjustment required
Common Pitfall to Avoid
Do not automatically reduce Rexulti dose when adding an SSRI. The FDA labeling is nuanced: while paroxetine/fluoxetine are strong CYP2D6 inhibitors that increase brexpiprazole levels, dose adjustment is NOT required in the MDD/anxiety context because clinical trials used standard dosing with these combinations 1. However, if using fluvoxamine (CYP3A4 inhibitor), you MUST reduce the Rexulti dose by 50% 1.